Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche Group member, Genentech's phase III AVAglio study has met its co-primary endpoint of improving progression-free survival (PFS) in people with Glioblastoma.
Subscribe to our email newsletter
AVAglio Phase III is a randomized, double-blind, placebo controlled trial that has assessed the efficacy and safety profile of Avastin in combination with radiation and temozolomide chemotherapy.
In the study, Avastin has extended the time of people when compared to people treated with radiation and temozolomide chemotherapy plus placebo.
The final data of overall survival (OS), the other co-primary endpoint is expected to be available in 2013.
Avastin is currently approved in the US to treat adults with glioblastoma who have progressive disease following prior therapy.
Roche Global Product Development head and chief medical officer Hal Barron said, "This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy."
According to Genetech, Roche and Genetech have plans to discuss these Phase III results with European Medicines Agency and FDA.